EGF

Association between the EGF rs4444903 polymorphism and liver cancer susceptibility: a meta-analysis and meta-regression

Y. L. Li, Tian, Z., Zhao, L., and Zhang, C. L., Association between the EGF rs4444903 polymorphism and liver cancer susceptibility: a meta-analysis and meta-regression, vol. 13, pp. 8066-8079, 2014.

Emerging evidence suggests that a common functional polymorphism, rs4444903 (A>G), in the EGF gene might impact an individual’s susceptibility to liver cancer; however, individually published results are inconclusive. This meta-analysis aimed to derive a more precise estimation of the relationship between the EGF rs4444903 polymorphism and liver cancer risk. A literature search was conducted in the PubMed, Embase, Web of Science, and CBM databases from inception through May 1st, 2013.

Genetic polymorphisms of EGF 5'-UTR and NAT2 857G/A associated with glioma in a case control study of Malaysian patients

K. A. Muthusamy, Lian, L. H., Vairavan, N., Chua, K. H., and Waran, V., Genetic polymorphisms of EGF 5'-UTR and NAT2 857G/A associated with glioma in a case control study of Malaysian patients, vol. 11, pp. 2939-2945, 2012.

Studies of genetic mutations that have been used in predicting glioma prognosis have revealed a complex relationship between clinical and genetic factors. Epidermal growth factor (EGF) and the NAT2 gene play a central role in carcinogenesis. An adenine (A) to guanine (G) single nucleotide polymorphism at position 61 in the 5'-untranslated region (5'-UTR) of the EGF gene has been found to be associated with levels of EGF production, and the mutations in the NAT2 gene have been postulated as a risk factor for cancer.

Subscribe to EGF